ORIC · Oric Pharmaceuticals, Inc.
The AI's read
The tumor reductions across different mutations, including in the brain, give ORIC encouraging evidence that enozertinib may help patients. Six patients had grade 3 side effects, but all resolved after dose changes, and no one stopped treatment because of side effects. Important questions remain. The study included 26 patients, survival results are incomplete, and the larger study is only planned for 2027. The reported tumor activity still supports a positive reading for ORIC.